Journal
BRITISH JOURNAL OF CANCER
Volume 114, Issue 4, Pages 362-367Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2015.435
Keywords
antibody-drug conjugate; target antigen; cytotoxic payload; linker; T-DM1; brentuximab vedotin; MMAE; resistance
Categories
Funding
- Cancer Research UK
- Experimental Cancer Medicine Centre
- National Institute for Health Research Biomedical Research Centre
- Hellenic Society of Medical Oncology (HESMO)
Ask authors/readers for more resources
Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. New linker technology associated with novel highly potent cytotoxic payloads has permitted the development of more effective and safe ADCs. In recent years, two ADCs have been licensed, T-DM1 and brentuximab vedotin, and are already establishing their place in cancer treatment. A plethora of ADCs are being investigated in phases I and II trials, emerging data of which appears promising. As we deepen our understanding of what makes a successful ADC, an increasing number of ADCs will likely become viable treatment options as single agents or in combination with chemotherapy. This review will present the philosophy underlying ADCs, their main characteristics and current research developments with a focus on ADCs in solid tumours.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available